420 with CNW — UC San Diego Research Explores Ca
Post# of 182
(Total Views: 519)
Posted On: 06/12/2021 5:15:48 AM
420 with CNW — UC San Diego Research Explores Cannabis Use Against Migraines
Long before America had a growing state-legal cannabis sector, regular users claimed the controversial drug was a great pain relief option. With more than 30 states now allowing the use of medical marijuana, thousands of patients have been able to get a taste of cannabis’ alleged pain-relief abilities. However, due to marijuana’s controlled status at the federal level, researchers have been unable to have a more conclusive look at its purported medical abilities — until recently.
Now, a group of researchers at UC San Diego is taking advantage of its state’s pro-cannabis legislation to launch the first placebo-controlled study into how migraines react to different cannabis strains. The Centers for Disease Control and Prevention (“CDC”) estimates that approximately 15.3% of the American population suffers from migraines, with pharmaceuticals being the only treatment option. Although plenty of users claim that cannabis works just as well as pharmaceuticals against migraines, research has been severely limited because the substance is still illegal at the federal level.
However, California allows both recreational and medical cannabis, and the team from UC San Diego is taking advantage of the situation. Led by Dr. Nathaniel Schuster, the researchers have been working with government authorities for several years to obtain the approval they needed. With the government also supplying medical-grade cannabis to be used in the study, the researchers give participants four different doses, each to be used on a separate kind of headache.
Each participant will be given a dose of cannabis with THC, one with a CBD/THC blend, one with just CBD and one with a placebo. They will not know what is contained within each dose, Schuster explains, and they will record their results with each dose via an app. Up to 30% of medical marijuana users take cannabis to alleviate some form of headache, says Schuster, who hopes his study will finally provide concrete data behind the escalating practice of using cannabis for pain relief.
Dr. Jack Schrim, co-director of the Headache Center of Southern California, is a big fan of the study, and he has already referred several patients who wish to take part. Although many of his patients have asked him about using cannabis to alleviate their migraines, he is often unable to make any recommendations because there is little scientific data in the area. Fortunately, the UC San Diego study seeks to provide this information, and study results will help society better understand the link between cannabinoid receptors and cannabis treatments.
Individuals who wish to participate in the study must be affected by migraines at least once a month, and they cannot be regular cannabis or opioid users. If you meet these requirements, you can contact the Research Coordinator Phirum Nguyen at psnguyen@ucsd.edu or 858-822-3108.
Cannabis firms that serve both the recreational and medicinal cannabis markets, such as Grapefruit USA Inc. (OTCQB: GPFT), are likely to see an uptick in sales if this research finds conclusive evidence of the claims that marijuana has migraine-relieving properties.
NOTE TO INVESTORS: The latest news and updates relating to Grapefruit USA Inc. (OTCQB: GPFT) are available in the company’s newsroom at http://cnw.fm/GPFT
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Long before America had a growing state-legal cannabis sector, regular users claimed the controversial drug was a great pain relief option. With more than 30 states now allowing the use of medical marijuana, thousands of patients have been able to get a taste of cannabis’ alleged pain-relief abilities. However, due to marijuana’s controlled status at the federal level, researchers have been unable to have a more conclusive look at its purported medical abilities — until recently.
Now, a group of researchers at UC San Diego is taking advantage of its state’s pro-cannabis legislation to launch the first placebo-controlled study into how migraines react to different cannabis strains. The Centers for Disease Control and Prevention (“CDC”) estimates that approximately 15.3% of the American population suffers from migraines, with pharmaceuticals being the only treatment option. Although plenty of users claim that cannabis works just as well as pharmaceuticals against migraines, research has been severely limited because the substance is still illegal at the federal level.
However, California allows both recreational and medical cannabis, and the team from UC San Diego is taking advantage of the situation. Led by Dr. Nathaniel Schuster, the researchers have been working with government authorities for several years to obtain the approval they needed. With the government also supplying medical-grade cannabis to be used in the study, the researchers give participants four different doses, each to be used on a separate kind of headache.
Each participant will be given a dose of cannabis with THC, one with a CBD/THC blend, one with just CBD and one with a placebo. They will not know what is contained within each dose, Schuster explains, and they will record their results with each dose via an app. Up to 30% of medical marijuana users take cannabis to alleviate some form of headache, says Schuster, who hopes his study will finally provide concrete data behind the escalating practice of using cannabis for pain relief.
Dr. Jack Schrim, co-director of the Headache Center of Southern California, is a big fan of the study, and he has already referred several patients who wish to take part. Although many of his patients have asked him about using cannabis to alleviate their migraines, he is often unable to make any recommendations because there is little scientific data in the area. Fortunately, the UC San Diego study seeks to provide this information, and study results will help society better understand the link between cannabinoid receptors and cannabis treatments.
Individuals who wish to participate in the study must be affected by migraines at least once a month, and they cannot be regular cannabis or opioid users. If you meet these requirements, you can contact the Research Coordinator Phirum Nguyen at psnguyen@ucsd.edu or 858-822-3108.
Cannabis firms that serve both the recreational and medicinal cannabis markets, such as Grapefruit USA Inc. (OTCQB: GPFT), are likely to see an uptick in sales if this research finds conclusive evidence of the claims that marijuana has migraine-relieving properties.
NOTE TO INVESTORS: The latest news and updates relating to Grapefruit USA Inc. (OTCQB: GPFT) are available in the company’s newsroom at http://cnw.fm/GPFT
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
(0)
(0)